Related Experiment Video
Updated: May 11, 2026
A Mouse Model to Assess Innate Immune Response to Staphylococcus aureus Infection
Published on: February 28, 2019
A single polypeptide vaccine derived from multiple antigens confers protection against staphylococcus aureus
Celia Hoi-Ching Chan1, Ying Dou1, Renhao Li1,2
1School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
Abstract:
The emergence of Methicillin-resistance Staphylococcus aureus (MRSA) has posed a crucial threat in healthcare systems worldwide. Vaccination is ideal prevention against infection from antibiotic-resistance bacteria such as MRSA. Unfortunately, the development of S. aureus vaccine has faced tremendous challenges, suffering from repetitive failure of clinical trials. In this study, we formulated a panel of single polypeptide vaccines Sta-V5*1-3 based on a multi-valent S. aureus vaccine Sta-V5 previously developed by our team. The single polypeptide vaccines composed of antigen fragments induced robust humoral responses and protective immunity against MRSA infection in multiple animal disease models with indistinguishable efficacy when compared with Sta-V5 vaccine. We also attempted to formulate an epitope vaccine Sta-V5-EP based on T cell and B cell epitopes of antigens from Sta-V5. However, Sta-V5-EP failed to elicit sufficient protection in mouse model. Taken together, design of Sta-V5* vaccines represent a valuable S. aureus vaccine platform that avoids the laborious purification of multiple antigens and contamination with impurities.
Insights
New single polypeptide vaccines (Sta-V5*) show promise against Methicillin-resistant Staphylococcus aureus (MRSA) infections. These vaccines offer robust immunity in animal models, presenting a valuable alternative to traditional multi-antigen approaches.
Area of Science:
- Microbiology
- Immunology
- Vaccine Development
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) presents a significant global healthcare challenge.
- Effective vaccines are crucial for preventing infections by antibiotic-resistant bacteria like MRSA.
- Previous S. aureus vaccine development efforts have encountered substantial clinical trial failures.
Purpose of the Study:
- To develop and evaluate novel single polypeptide vaccines (Sta-V5*1-3) derived from a previously established multi-valent vaccine (Sta-V5).
- To assess the immunogenicity and protective efficacy of these new vaccine candidates against MRSA.
- To compare the performance of single polypeptide vaccines with the original multi-valent vaccine and an epitope-based vaccine.
Main Methods:
- Formulation of single polypeptide vaccines (Sta-V5*1-3) using antigen fragments from S. aureus.
- Development of an epitope-based vaccine (Sta-V5-EP) utilizing T cell and B cell epitopes.
- Evaluation of humoral responses and protective immunity in multiple animal models of MRSA infection.
- Comparative efficacy analysis between Sta-V5*, Sta-V5, and Sta-V5-EP vaccines.
Main Results:
- Single polypeptide vaccines (Sta-V5*1-3) induced strong humoral responses and provided significant protection against MRSA.
- The efficacy of Sta-V5* vaccines was comparable to the original Sta-V5 vaccine in animal models.
- The epitope-based vaccine (Sta-V5-EP) failed to elicit sufficient protection in a mouse model.
- Sta-V5* vaccines demonstrated comparable efficacy to the multi-valent Sta-V5 vaccine.
Conclusions:
- The Sta-V5* vaccine platform offers a promising strategy for S. aureus vaccine development.
- These single polypeptide vaccines simplify production by avoiding complex antigen purification.
- The Sta-V5* platform provides a valuable alternative, mitigating risks of impurity contamination associated with multi-antigen vaccines.
Related Concept Videos
01:25Clinical Significance of Antibiotic Resistance
01:21Vaccines